Overview MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary Estimate of clinical and microbiological efficacy of Levofloxacin (Tavanic) in combine therapy of MDR TB. Estimate of safety of Levofloxacin (Tavanic) in combine therapy of MDR TB. Phase: Phase 4 Details Lead Sponsor: SanofiTreatments: LevofloxacinOfloxacin